Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHUC Charlie's	$0.10 -5.1%	$0.10	$0.03 ▼ $0.19	$25.79M	0.93	75,460 shs	15,021 shs
COYA Coya Therapeutics	$6.27 +8.4%	$5.83	$4.65 ▼ $10.24	$104.81M	0.26	72,443 shs	72,677 shs
CTNM Contineum Therapeutics	$3.98 -0.6%	$4.08	$3.35 ▼ $21.92	$102.83M	0.85	90,707 shs	143,855 shs
JSPR Jasper Therapeutics	$7.04 +3.2%	$5.36	$3.13 ▼ $26.05	$105.68M	2.69	315,538 shs	336,840 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHUC Charlie's	0.00%	-0.30%	-7.12%	+65.33%	-41.65%
COYA Coya Therapeutics	0.00%	+7.09%	+6.55%	+16.23%	-3.62%
CTNM Contineum Therapeutics	0.00%	-3.28%	-16.32%	-25.98%	-80.15%
JSPR Jasper Therapeutics	0.00%	+28.16%	+17.07%	+97.09%	-66.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHUC Charlie's	0.1929 of 5 stars	0.0	3.0	0.0	1.7	0.0
COYA Coya Therapeutics	2.3083 of 5 stars	3.5	4.0	1.9	0.8	0.0
CTNM Contineum Therapeutics	2.1669 of 5 stars	3.6	1.0	0.0	0.8	1.3
JSPR Jasper Therapeutics	2.0176 of 5 stars	3.5	3.0	1.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHUC Charlie's	0.00	N/A	N/A	N/A
COYA Coya Therapeutics	3.00	Buy	$16.67	166.03% Upside
CTNM Contineum Therapeutics	3.17	Buy	$22.50	466.04% Upside
JSPR Jasper Therapeutics	3.00	Buy	$59.25	742.10% Upside

Current Analyst Ratings Breakdown

Latest CHUC, JSPR, CTNM, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/13/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHUC Charlie's	$8.49M	3.04	N/A	N/A	($0.01) per share	-9.92
COYA Coya Therapeutics	$3.55M	29.52	N/A	N/A	$2.37 per share	2.64
CTNM Contineum Therapeutics	$50M	2.06	N/A	N/A	$7.66 per share	0.52
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHUC Charlie's	-$4.16M	-$0.01	N/A	∞	N/A	-55.89%	N/A	-104.63%	8/18/2025 (Estimated)
COYA Coya Therapeutics	-$14.88M	-$1.07	N/A	N/A	N/A	N/A	-48.88%	-43.32%	8/11/2025 (Estimated)
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
JSPR Jasper Therapeutics	-$71.27M	-$5.24	N/A	N/A	N/A	N/A	-109.45%	-89.82%	8/12/2025 (Estimated)

Latest CHUC, JSPR, CTNM, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2024	CHUC Charlie's	N/A	-$0.01	N/A	-$0.01	N/A	$1.78 million
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHUC Charlie's	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHUC Charlie's	N/A	0.51	0.06
COYA Coya Therapeutics	N/A	8.84	8.84
CTNM Contineum Therapeutics	N/A	21.47	21.47
JSPR Jasper Therapeutics	N/A	4.31	4.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHUC Charlie's	7.80%
COYA Coya Therapeutics	39.75%
CTNM Contineum Therapeutics	N/A
JSPR Jasper Therapeutics	79.85%

Insider Ownership

Company	Insider Ownership
CHUC Charlie's	20.90%
COYA Coya Therapeutics	12.00%
CTNM Contineum Therapeutics	11.30%
JSPR Jasper Therapeutics	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHUC Charlie's	40	259.95 million	205.62 million	Not Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable

CHUC, JSPR, CTNM, and COYA Headlines

Recent News About These Companies

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $62.22 Consensus Price Target from Analysts

June 28, 2025 | americanbankingnews.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from Brokerages

June 25, 2025 | marketbeat.com

Jasper Therapeutics stock maintains buy rating on positive urticaria data

June 18, 2025 | investing.com

Jasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible Urticaria

June 15, 2025 | nasdaq.com

Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinized

June 15, 2025 | investing.com

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

June 14, 2025 | globenewswire.com

Analysts Offer Predictions for JSPR FY2026 Earnings

June 10, 2025 | marketbeat.com

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

June 3, 2025 | globenewswire.com

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

May 29, 2025 | finance.yahoo.com

Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential

May 21, 2025 | insidermonkey.com

Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development

May 16, 2025 | nasdaq.com

Jasper Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025 | globenewswire.com

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 5.34%

May 6, 2025 | aaii.comA

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.05%

April 22, 2025 | aaii.comA

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.55%

April 11, 2025 | aaii.comA

Jasper Therapeutics inks new sales agreement, ends previous deal

March 21, 2025 | uk.investing.com

Jasper Therapeutics files $300M mixed securities shelf

March 19, 2025 | markets.businessinsider.com

Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study

March 2, 2025 | msn.com

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

March 1, 2025 | globenewswire.com

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

February 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHUC, JSPR, CTNM, and COYA Company Descriptions

Charlie's OTCMKTS:CHUC

$0.10 -0.01 (-5.07%)

As of 07/3/2025 12:22 PM Eastern

Charlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.

Coya Therapeutics NASDAQ:COYA

$6.26 +0.49 (+8.39%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$6.05 -0.22 (-3.50%)

As of 07/3/2025 04:01 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Contineum Therapeutics NASDAQ:CTNM

$3.98 -0.03 (-0.63%)

Closing price 07/3/2025 02:42 PM Eastern

Extended Trading

$4.07 +0.10 (+2.42%)

As of 07/3/2025 04:13 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Jasper Therapeutics NASDAQ:JSPR

$7.04 +0.22 (+3.17%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$6.90 -0.13 (-1.86%)

As of 07/3/2025 04:48 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time